by Agne Straukiene
This EAN TV session delivered an unusually rich and human‑centred exploration of three conditions that profoundly affect daily life: narcolepsy, ME/CFS and restless legs syndrome. What made the discussion stand out was the blend of clinical expertise and lived experience, creating a session that felt both scientifically grounded and emotionally resonant.
The narcolepsy segment was particularly engaging. The patient representative described how awareness has transformed over the past decades from being handed an incomprehensible leaflet to now having accessible social‑media campaigns and clear educational videos. Her reflections on cataplexy, automatic behaviours, and the limits of wearables were refreshingly honest. The idea that simple digital tools like an app to log sleep attacks could meaningfully support patients was one of the session’s most practical insights.
The ME/CFS discussion was striking for its clarity. The speaker explained the condition through the lens of neuroinflammation and mitochondrial dysfunction, offering a coherent narrative that many clinicians still lack. There were powerful examples from patients bedbound for years who were slowly regaining function. Telemedicine emerged as essential for this population, though the limits of remote assessment were acknowledged. The emphasis on pacing, personalised thresholds, and physiotherapist‑guided digital tools provided much‑needed nuance.
The restless legs syndrome segment added a compelling clinical perspective. The speaker challenged the trivialising name and vividly described how nightly symptoms cascade into daytime cognitive impairment. His comparison to long‑haul flight discomfort was memorable and effective. The discussion on iron metabolism, augmentation from dopamine agonists, and the potential role of AI‑supported screening highlighted how digital innovation may help, but only with careful clinical oversight.
Overall, this session offered a thoughtful and relatable overview of three conditions often misunderstood or underestimated. It balanced science, patient experience, and digital innovation in a way that felt genuinely useful for clinicians and patients alike.
Watch the session below, or on our Vimeo channel, here: EFNA: Epidemiology, diagnosis and trials for rare neurology
